Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Recurrence × avelumab × Clear all

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 10 Neoplasm Metastasis 10 Carcinoma, Transitional Cell 10 Breast Neoplasms 9 Carcinoma, Merkel Cell 8 Neoplasms 7 Carcinoma, Renal Cell 7 Head and Neck Neoplasms 6 Colorectal Neoplasms 6 Carcinoma, Non-Small-Cell Lung 5 Neuroendocrine Tumors 4 Triple Negative Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Skin Neoplasms 3 Prostatic Neoplasms 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Neuroendocrine 3 Carcinoma, Hepatocellular 3 Urethral Neoplasms 2 Ureteral Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Penile Neoplasms 2 Pancreatic Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasm, Residual 2 Mesothelioma, Malignant 2

Interventions

Cyclophosphamide 101 Dexamethasone 54 Cytarabine 47 fludarabine phosphate 45 fludarabine 44 Rituximab 44 Gemcitabine 34 Peripheral Blood Stem Cell Transplantation 32 Lenalidomide 32 Etoposide 32 pembrolizumab 30 Radiotherapy 29 Filgrastim 29 Busulfan 28 Cyclosporine 26 Methotrexate 25 Melphalan 25 Carboplatin 25 Cisplatin 24 venetoclax 23 Mycophenolic Acid 23 Paclitaxel 22 Bortezomib 22 Whole-Body Irradiation 21 Granulocyte Colony-Stimulating Factor 20 Bevacizumab 20 Antilymphocyte Serum 19 Temozolomide 18 Oxaliplatin 17 Decitabine 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04562441 2025-01-10

NPC - AXEL Study : Axitinib-Avelumab

Chinese University of Hong Kong

Phase 2 Completed

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡